MVD Inhibitors

MVD Inhibitors primarily revolve around the manipulation of the mevalonate pathway, essential for the synthesis of several bioactive molecules in the cell. The majority of the chemicals, such as Lovastatin, Simvastatin, and Atorvastatin, are statins which are specifically designed to inhibit the enzyme HMG-CoA reductase, an early step enzyme in the mevalonate pathway. By inhibiting the early stages of the pathway, these chemicals can indirectly impact the function or importance of MVD. Moreover, another group of compounds, bisphosphonates, like Alendronate and Zoledronate, target farnesyl diphosphate synthase. This action again indirectly affects MVD because both enzymes function in the same pathway. Finally, compounds like GGTI-298 and FTI-277 target the prenylation of proteins, a process downstream of the mevalonate pathway. By influencing these downstream effects, they indirectly emphasize the importance of upstream enzymes like MVD.